Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?
作者信息
Jorgensen Sarah C J, Burry Lisa, Tse Christopher L Y, Dresser Linda D
机构信息
Department of Pharmacy, Sinai Health System, Toronto, Ontario, Canada.
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
出版信息
Clin Infect Dis. 2021 Dec 6;73(11):e3978-e3979. doi: 10.1093/cid/ciaa1208.
Abstract
摘要
相似文献
1
Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?巴瑞替尼：对2019冠状病毒病（COVID-19）凝血障碍有何影响？
Clin Infect Dis. 2021 Dec 6;73(11):e3978-e3979. doi: 10.1093/cid/ciaa1208.
2
Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al.对信件的回复：巴瑞替尼：对2019冠状病毒病（COVID-19）凝血障碍有何影响？约根森等人
Clin Infect Dis. 2021 Dec 6;73(11):e3980-e3981. doi: 10.1093/cid/ciaa1210.
3
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.巴瑞替尼在中重度 2019 冠状病毒病患者中的应用。
Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. doi: 10.1093/cid/ciaa879.
4
Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas?巴瑞替尼治疗2019冠状病毒病（COVID-19）：胰腺的朋友还是敌人？
Clin Infect Dis. 2021 Dec 6;73(11):e3977-e3978. doi: 10.1093/cid/ciaa1209.
5
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.巴瑞替尼：在一项安慰剂对照试验中首个降低新冠肺炎死亡率的免疫调节治疗药物。
Lancet Respir Med. 2021 Dec;9(12):1349-1351. doi: 10.1016/S2213-2600(21)00358-1. Epub 2021 Sep 1.
6
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?评论：古杜·T、斯托伯·C、科普·AP等人。巴瑞替尼即将加入新冠治疗武器库？
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
7
Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary.住院的老年和非老年严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 患者接受巴瑞替尼治疗后的继发感染和长期结局：来自匈牙利国家中心的一项比较研究。
Geroscience. 2024 Jun;46(3):2863-2877. doi: 10.1007/s11357-024-01099-y. Epub 2024 Feb 17.
8
Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study.巴瑞替尼治疗 COVID-19 合并呼吸衰竭患者的效果：一项倾向评分匹配的回顾性队列研究。
Respir Investig. 2022 May;60(3):418-424. doi: 10.1016/j.resinv.2022.02.004. Epub 2022 Mar 7.
9
Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.巴瑞替尼治疗新冠病毒肺炎——满足一项未被满足的需求
N Engl J Med. 2021 Mar 4;384(9):867-869. doi: 10.1056/NEJMe2034982.
10
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
引用本文的文献
1
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.COVID-19 患者中 JAK1/2 抑制剂芦可替尼引发的过度炎症：RuxCoFlam 试验。
Leukemia. 2023 Sep;37(9):1879-1886. doi: 10.1038/s41375-023-01979-w. Epub 2023 Jul 28.
2
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials.Janus 激酶抑制剂与主要 COVID-19 结局：是时候忘记两面神 Janus 了！随机对照试验的荟萃分析。
Clin Rheumatol. 2021 Nov;40(11):4671-4674. doi: 10.1007/s10067-021-05884-4. Epub 2021 Aug 24.
Zotero 插件